Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Corticoids in Severe Community-Acquired Pneumonia (CAP)

Phase 4

Completed

Conditions: Community-Acquired Pneumonia

Interventions: Drug: Placebo
Drug: methylprednisolone

First Posted Date: 2009-05-27

Last Posted Date: 2013-03-20

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 120

Registration Number: NCT00908713

Locations: 🇪🇸
Servei Pneumoloiga. Hospital Clinic, Barcelona, Catalunya, Spain
🇪🇸
Servei Pneumologia. Hospital Clinic, Barcelona, Catalunya, Spain
🇪🇸
Hospital Clinic, Barcelona, Spain

Desensitization in Kidney Transplantation

Phase 4

Completed

Conditions: HLA Sensitization

Interventions: Drug: plasmapheresis
Drug: Bortezomib
Drug: Rituximab
Drug: Methylprednisolone

First Posted Date: 2009-05-27

Last Posted Date: 2016-04-01

Lead Sponsor: University of Cincinnati

Target Recruit Count: 44

Registration Number: NCT00908583

Locations: 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Phase 2

Completed

Conditions: Familial Lipoprotein Lipase Deficiency

Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Drug: mycophenolate mofetil
Drug: cyclosporine
Drug: methylprednisolone

First Posted Date: 2009-05-01

Last Posted Date: 2011-09-29

Lead Sponsor: Amsterdam Molecular Therapeutics

Target Recruit Count: 5

Registration Number: NCT00891306

Locations: 🇨🇦
ECOGENE-21 Clinical Trial Center / Centre de santé et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada
🇨🇦
Centre des Maladies Lipidiques de Québec, Quebec, Canada

Influence of Corticoids on Renal Function in Cardiac Surgery

Phase 2

Completed

Conditions: Elective Cardiac Surgery

Interventions: Drug: Placebo
Drug: Methylprednisolone

First Posted Date: 2009-04-13

Last Posted Date: 2022-12-07

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 80

Registration Number: NCT00879931

Locations: 🇧🇪
University Hospital Ghent, Ghent, Belgium

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Infliximab
Drug: Methylprednisolone
Drug: Ocrelizumab
Drug: Placebo

First Posted Date: 2008-12-15

Last Posted Date: 2020-11-06

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 28

Registration Number: NCT00808210

Locations: 🇺🇸
Ohio State Univ Med Center, Columbus, Ohio, United States
🇺🇸
Ctr for Inflammatory Disease, Nashville, Tennessee, United States
🇺🇸
Phillip A Waller MD, PA, Houston, Texas, United States

and more 49 locations

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Aplastic Anemia

Interventions: Drug: Thymoglobulin
Drug: Cyclosporine
Drug: Methylprednisolone
Drug: G-CSF

First Posted Date: 2008-12-11

Last Posted Date: 2013-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00806598

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Assessment of the Operative Course in Connection With Removal of Lower Third Molars

Not Applicable

Completed

Conditions: Postoperative Pain
Inflammation

Interventions: Drug: methylprednisolone
Drug: placebo
Drug: xyloplyin adrenalin
Drug: marcain adrenalin

First Posted Date: 2008-12-09

Last Posted Date: 2012-10-24

Lead Sponsor: University of Aarhus

Target Recruit Count: 154

Registration Number: NCT00805298

Locations: 🇩🇰
School of Dentistry, Aarhus University, Aarhus, Denmark

Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Phase 2

Completed

Conditions: Meniere's Disease

Interventions: Drug: Methylprednisolone
Drug: Gentamicin

First Posted Date: 2008-12-05

Last Posted Date: 2019-06-27

Lead Sponsor: Imperial College London

Target Recruit Count: 60

Registration Number: NCT00802529

Locations: 🇬🇧
Imperial college Healthcare NHS Trust, London, United Kingdom

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

First Posted Date: 2008-11-18

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT00792948

Locations: 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸
Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States

and more 154 locations

Hematopoietic Stem Cell Transplant in Devic's Disease

Phase 1

Completed

Conditions: Devic's Disease

Interventions: Procedure: Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: G-CSF
Drug: rATG
Drug: Mesna
Drug: Rituximab
Drug: Methylprednisolone

First Posted Date: 2008-11-07

Last Posted Date: 2020-02-28

Lead Sponsor: Northwestern University

Target Recruit Count: 13

Registration Number: NCT00787722

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy